Orthovisc is one of the hyaluronates used in a procedure known as viscosupplementation. Orthovisc is a non-animal sourced viscosupplement that is injected directly into the knee joint to restore the cushioning and lubricating properties of the normal joint fluid (i.e., synovial fluid).
Indications
Orthovisc was approved by the Food and Drug Administration (FDA) on February 4, 2004, for the treatment of pain associated with knee osteoarthritis in patients who failed to achieve adequate relief with more conservative treatment (e.g., exercise, physical therapy) and the use of simple analgesics, such as acetaminophen.
Orthovisc is considered a medical device, not a drug, as is the case with other hyaluronates used in viscosupplementation. Orthovisc is administered as a series of three or four weekly intra-articular injections. According to the manufacturer of Orthovisc, it can produce beneficial effects that last up to 26 weeks.
Contraindications
People with a known hypersensitivity to hyaluronan products should not be treated with Orthovisc or any of the viscosupplements. Also, people with a known allergy to birds or bird products should not use Orthovisc. (Note: This warning is applied to all hyaluronan products.) People with an infection in the knee joint, other infection, or skin disease in the area where the injection would be given should not be treated with Orthovisc.
Common Side Effects and Adverse Events
The most common adverse events associated with Orthovisc treatment during clinical studies included arthralgia, back pain, and headache. Other adverse events were local injection site reactions
Precautions and Warnings
As with any intra-articular injection, it is recommended that the patient avoid strenuous activities or prolonged weight-bearing activities for 48 hours. Also, it should be noted that pain or swelling may occur after the injection, but normally it will diminish after a short time period. Also noteworthy, the safety and effectiveness of Orthovisc have not been established in pregnant women, lactating women, or children.
The Bottom Line
Other FDA-approved viscosupplements, along with the date they were approved, include:
Hyalgan 05/28/1997 Synvisc 08/08/1997 Supartz 01/24/2001 Euflexxa 12/03/2004
According to the American Association of Orthopaedic Surgeons (AAOS) the most recent research has not found viscosupplementation to be effective at significantly reducing pain or improving function, although some patients report pain relief.
It has been suggested that viscosupplementation has the best chance of being effective when arthritis is in its early stages (i.e., mild to moderate knee osteoarthritis). Even so, the American College of Rheumatology and the Arthritis Foundation conditionally recommend against intra-articular hyaluronic acid injections for knee arthritis.
